Genmab | GEN - Current Assets


Genmab reported DKK2.88B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Almirall EUR 713.98M 69K Dec/2025
Amarin USD 626.02M 23.87M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
argenx SE USD 6.9B 1.07B Dec/2025
AstraZeneca USD 29.61B 890M Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Demant DKK 10.08B 128M Dec/2025
Exelixis USD 1.21B 234.65M Mar/2026
Fresenius Medical Care EUR 8.11B 209.55M Mar/2026
Genmab DKK 2.88B 1.59B Dec/2025
GlaxoSmithKline GBP 17.76B 251M Mar/2026
GN Store Nord DKK 4.85B 3.79B Mar/2026
GRIFOLS EUR 5.25B 180M Mar/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Insmed USD 1.61B 181.04M Mar/2026
Lakefront Biotherapeutics EUR 3.06B 18.72M Mar/2026
Lonza CHF 8B 3.41B Dec/2025
Merck EUR 13.23B 354M Dec/2025
Novartis USD 26.61B 3.85B Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.16B 789M Mar/2026
UCB EUR 6.05B 733M Dec/2025